Patient Case 1 Peggy Peggy Interactive Case Question.

Slides:

Advertisements

Similar presentations

Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes.

Advertisements

Analogs as a Focus Bruce W. Bode, MD, FACE Atlanta Diabetes Associates Atlanta, Georgia.

Inhaled Human Insulin Treatment in Patients with Type 2 Diabetes Mellitus Matthew Faiman.

Long-Term Efficacy of Dapagliflozin in T2DM Patients Receiving High-Dose Insulin John P.H. Wilding, DM, FRCP 

Basal Bolus: The Strategy for Managing All Diabetes Fall, 2003 Paul Davidson, MD, FACE Atlanta Diabetes Associates Atlanta, Georgia.

Endocrine and Metabolic Disorders Lectures 8 I.Kuziv, MD, PhD.

New Insulin Formulations Guillermo Umpierrez, MD, FACP, FACE Professor of Medicine Emory University School of Medicine Part 1.

An Educational Service from GlycoMark

Insulins Roland Halil, BScPharm, ACPR, PharmD Clinical Pharmacist, Bruyere Academic Family Health Team Assistant Professor, Dept of Family Medicine, U.

Safety and Efficacy of Sitagliptin Therapy for the Inpatient Management of General Medicine and Surgery Patients With Type 2 Diabetes A pilot, randomized,

Biphasic insulin aspart 30 + metformin vs once-daily insulin glargine + glimepiride Kann P, Regulski M, Medding J, Ligthelm R A study in people with type.

Journal Club 亀田メディカルセンター糖尿病内分泌内科 Diabetes and Endocrine Department, Kameda Medical Center 松田昌文 Matsuda, Masafumi 2008 年５月１日 8:20-8:50 B 棟８階カンファレンス室.

Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled With Newly Initiated and Continuously Titrated Basal Insulin Glargine A 24-Week,

Changes in the concentration of serum C-peptide in type 2 diabetes during long-term continuous subcutaneous insulin infusion therapy Department of Internal.

Introduction Subcutaneous insulin absorption is not reproducible and insulin entry directly into the circulation is not linked to glucose sensing Basal.

Dr Ravi Kant Premix Analogue VS. Premix Human Insulin In Clinical Practice.

What's New in Basal Insulin for Diabetes

Dulaglutide vs Glargine, Both Combined with Lispro, Mitigated eGFR Decline in People with Type 2 Diabetes and Moderate-to-Severe Chronic Kidney Disease.

Key publication slides

Fig. 2. Change in (A) glycosylated hemoglobin (HbA1c) and (B) fasting plasma glucose (FPG). Group A: oral hypoglycemic agents (OHAs; sulfonylurea+metformin.

CAN WE IMPROVE POSTPRANDIAL GLUCOSE CONTROL WITH FAST-ACTING INSULINS?

Achieving Optimal Glycaemic Control: Can Insulin Deliver?

Key publication slides

Pharmacy Protocol for Insulin Dosing in the Hospitalized Patient

Blood Glucose, Lipids, and Coronary Artery Disease: Emerging Strategies for Multimechanistic Treatment.

Copyright © 2014 American Medical Association. All rights reserved.

Key publication slides

Recommendation In people with clinical cardiovascular disease in whom glycemic targets are not met, a SGLT2 inhibitor with demonstrated cardiovascular.

Long-term efficacy and safety of vildagliptin add-on therapy in type 2 diabetes mellitus with insulin treatment Ippei Kanazawa, Ken-ichiro Tanaka, Masakazu.

Key publication slides

Updates and Perspectives in Diabetic Dyslipidemia

Faster-Acting Insulins

Program Goals. Inhaled Insulin: Overcoming Past Obstacles With Advances in Understanding.

Figure 1: Patient inhaling Afrezza

SGLT2 Inhibitors: What Do the Data Mean for My Patients?

T1DM: Insulin Initiation

New Patient-Friendly Options for Managing Insulin Dosing

Utilizing New Technologies and Insulins for a Tighter Grip on PPG

Program Goals. Consulting the Experts: Prandial Insulin or a GLP-1 Receptor Agonist as Add-On to Basal Insulin.

SGLT2 Inhibitors in Phase 3 Trials

Clinical Advances in Type 2 Diabetes and Cardiovascular Risk

Novel Concentrated Insulins: What Benefits and for Which Patients?

Updates Abound.

Best Practices in Advanced Glucose Monitoring

What Do Primary Care Physicians Need to Know About Insulin/GLP-1 RA Fixed-Ratio Combinations?

Program Goals. What Will the Emerging Basal Insulin Products Mean for My Diabetes Practice?

Faster-Acting Insulins

Statins and Glucose Metabolism: Are All Agents Alike?

A Journal Club on Lipid Management:

Novel Basal Insulin Formulations in the Modern Era of T2D Management

Program Goals Overview Glatiramer Acetate 3 Times a Week.

Novel Approaches in T1D Management

Injectable Options as Add-Ons to Basal Insulin: Targeting PPG in Type 2 Diabetes Patients.

Simplifying Insulin Delivery for Better Patient Outcomes in T2D

Novel Approaches to T1D Management

Optimizing Insulin Therapy in Primary Care: Basal Plus Incretin Combinations.

Younger Patients With Type 1 Diabetes: Can We Optimize Their Insulin Therapy?

Approach to starting and adjusting insulin in type 2 diabetes.

Panelists. Cardiovascular Risk Modulation in Diabetes: Emerging Pathways and Insights.

Dual SGLT1/SGLT2 Inhibition in T1D

Liraglutide Shows CV Benefit: Clinical Perspectives on the LEADER Trial

Clinical Challenges and Updates in Managing Seizure Clusters

Flow of Patients Through Trial

Getting PPG Under Control

Emerging Combination Injectable Therapy A New Era in Diabetes Care

Type 1 Diabetes: Expanding Options for Adjunctive Oral Therapy With SGLT Inhibitors.

Statin Selection in Patients With Pre-Diabetes: Case Considerations

INSULINS Dr.R.Sajjad december INSULINS Dr.R.Sajjad december 2018.

A: PPG increment at week 26 for mealtime faster aspart versus IAsp.

Insulin in Type 2 Diabetes

Presentation transcript:

Patient Case 1 Peggy

Peggy Interactive Case Question

Clinical Considerations/Questions for Peggy

Adding Prandial Insulin in T2D

Patient Case 2 Jonathan

Jonathan Interactive Case Question

Clinical Considerations/Questions for Jonathan

LADA When T1D Masquerades as T2D

Adding Insulin in LADA

Case 3 Steven

Steven Interactive Case Question

Clinical Considerations for Steven

Case 4 Maria

Maria’s Blood Glucose Log

Identifying Hypoglycemic Events

Clinical Observations for Maria

Individualizing Prandial Insulin

Practical Discussions for Use of Prandial Insulin FAQs

Case 5 Michelle

Case 6 Jason

Rationale for and Limitations of Prandial Insulin Therapy in T2D

The Effect of Postmeal Hyperglycemia

Current and Emerging Prandial Insulins United States, September 2017

Timing of Prandial Insulin Injections

Inhaled Insulin (Technosphere®) in T2D

Efficacy and Safety of Inhaled Prandial Insulin Meta-Analysis

U-200 Lispro (in T1D)

Time-to-Peak Action Correlates With HbA1c

Current Insulin Treatment Challenges

Designing an Ultrafast-Acting Insulin

Changing the Formulation

Faster Aspart vs Insulin Aspart via SC Injection

Onset® 1 Trial Design

Onset® 1 Mean HbA1c Over Time

Onset® 1 Estimated Mean HbA1c Change From Baseline

Onset® 1 PPG Increment at Week 26

Onset® 2 Trial Design

Onset® 2 Mean HbA1c Over Time

Onset® 2 PPG Increment at Week 26

Comparing Faster Aspart and Insulin Aspart in CSII

PPG in CSII with Faster Aspart

BioChaperone Lispro

Ultra-Rapid Insulin Lispro

Summary

What Do the Data Mean, and How Will New Prandial Insulin Products Affect Practice?